ScreenerHero

BNTX BioNTech SE

NAS · US · Healthcare · Biotechnology · biontech.de
95.25USD-0.50%Mkt Cap: 23.93B $P/E: —

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also devel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
BBIO
BridgeBio Pharma, Inc.
$13.00BUSD

Key Statistics

Company
Market Cap23.93B USD
Enterprise Value10.90B USD
Revenue (TTM)2.65B USD
Gross Profit2.23B USD
Net Income (TTM)-1.14B USD
Revenue/Share10.69 USD
Last Price95.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.37
PEG0.05
EV/EBITDA-7.89
EV/Revenue4.11
P/S9.07
P/B1.21
EPS (TTM)-7.67
EPS (Forward)-5.51
52W Range
79.5235% of range124.00
52W High124.00 USD
52W Low79.52 USD
Profitability
Gross Margin77.64%
Oper. Margin-806.63%
EBITDA Margin-52.11%
Profit Margin-39.59%
ROE-5.91%
ROA-5.17%
Growth
Revenue Growth-59.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF456.00M USD
CapEx (TTM)749.00M USD
FCF Margin-9.42%
FCF Yield-1.04%
Net Debt-13.15B USD
Net Debt/EBITDA9.52
Balance Sheet
Debt/Equity0.01
Current Ratio7.85
Quick Ratio7.03
Book Value/Sh79.29 USD
Cash/Share53.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 2, 2022
Pay DateJun 17, 2022
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)116.07 USD
Upside (mean)+21.9%
Target Range73.26 USD – 139.76 USD
73.26+21.9% to mean139.76
# Analysts20
Ownership
Shares Out.251.20M
Float109.10M
Insiders57.24%
Institutions20.45%
Short Interest
Short Ratio1.4d
Short % Float3.48%
Short % Out.0.92%
Shares Short2.32M
Short (prev mo.)2.51M
Technical
SMA 5098.69 (-3.5%)
SMA 20097.73 (-2.5%)
Beta1.25
S&P 52W Chg16.45%
Avg Vol (30d)1.41M
Avg Vol (10d)883.67K
Technical Indicators
RSI (14)42.6
MACD-0.6831
MACD Signal-0.2163
MACD Hist.-0.4667
BB Upper100.53 USD
BB Middle97.75 USD
BB Lower94.96 USD
BB Width5.70%
ATR (14)3.501 USD
Vol Ratio (20d)0.95x